Drug Trial Radar · NCT01523301
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
Last checked: Nov 20, 2026Latest source record: Dec 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
380
Actual
Start
Apr 2012
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- UCB Korea Co., Ltd.UCB
- Sponsor type
- Industry
- First posted
- Feb 1, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.
Conditions
- Idiopathic Parkinson's Disease
Interventions
RotigotineDrug
Transdermal Patch Content: 2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2) * For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period * For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period
PlaceboDrug
Transdermal Patch Size: 10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2 Subjects randomized to placebo received matching placebo patches
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D)Time frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15)
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
03
Ansan, South Korea
19
Anyang, South Korea
08
Busan, South Korea
26
Busan, South Korea
04
Daegu, South Korea
05
Daegu, South Korea
16
Daejeon, South Korea
28
Goyang, South Korea
24
Gwangju, South Korea
29
Gwangju, South Korea
11
Gyeonggi-do, South Korea
15
Jinju, South Korea
23
Jungbuk, South Korea
01
Seoul, South Korea
02
Seoul, South Korea
06
Seoul, South Korea
07
Seoul, South Korea
09
Seoul, South Korea
10
Seoul, South Korea
12
Seoul, South Korea
13
Seoul, South Korea
14
Seoul, South Korea
17
Seoul, South Korea
18
Seoul, South Korea
20
Seoul, South Korea
21
Seoul, South Korea
22
Seoul, South Korea
27
Seoul, South Korea
25
Yangsan, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.